TGR5 receptor agonists are primarily used in the field of metabolic and liver diseases due to their ability to regulate bile acid signaling and glucose metabolism. These compounds are being investigated for their potential to treat type 2 diabetes by enhancing insulin secretion and improving glucose tolerance. Additionally, they show promise in managing non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) by reducing liver inflammation and improving lipid metabolism. TGR5 agonists are also explored for their anti-inflammatory properties, which could be beneficial in treating inflammatory bowel disease (IBD) and other chronic inflammatory conditions. Furthermore, they are studied for their role in promoting energy expenditure and weight loss, making them a potential candidate for obesity management. Research continues to explore their therapeutic applications in various metabolic and gastrointestinal disorders.